Secop Group and B Medical Systems announce cold chain solution partnership
A new agreement between Secop Group and B Medical Systems will provide new cold chain solutions for the transportation of vaccines, biospecimens and temperature-sensitive...
Defence Therapeutics have been granted patents for their antibody-drug conjugate technology
Defence Therapeutics is pleased to announce that notices of allowance have been issued by the Japanese and Israeli Patent Offices for patent application no....
Diagnostic technology is central to tackling pandemics
“Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” according to LumiraDx and the...
Accum A1-reprogrammed vaccine cured 80% of animals with pre-established lymphoma
Defence Therapeutics Inc, a Canadian biopharmaceutical company specialising in developing immune-oncology vaccines and drug delivery technologies, are pleased to report that Defence’s novel vaccine...
Defence Therapeutics applauds US President’s anti-cancer initiative
Defence Therapeutics Inc, a Canadian biotech company actively working on accelerating scientific discoveries an products development against cancer, congratulates US President, Joe Biden on...
LumiraDx’s COVID-19 antigen test is the only test exceeding WHO’s desirable sensitivity target
In a Cochrane meta-analysis of 152 studies investigating over 100,000 nose and throat samples and 20 brands of COVID-19 tests, only the LumiraDx assay...
Defence’s ACCUMTM variant “A1” converts mesenchymal stromal cells into potent antigen presenting cells
Defence Therapeutics has announced groundbreaking news about the development of a novel anti-cancer cellular vaccine using reprogrammed mesenchymal stromal cells.
Defence Therapeutics Inc., a Canadian...
Azenta announces acquisition of B Medical Systems
Azenta Inc. has announced its agreement to acquire B Medical Systems, a market leader in temperature-controlled storage and transportation solutions.
In an exciting development, Azenta...
Defence Therapeutics receives US patent for its ADC Platform Technology
In an exciting development, Defence Therapeutics has received a US patent covering its ADC Platform Technology.
In the latest announcement on August 8th, 2022, Defence...
ACCUTOXTM effectively eliminates cancer cells by eliciting DNA damage
In a potentially monumental breakthrough in the war against cancer, Defence Therapeutics has revealed that its leading AccuTOXTM compound effectively kills cancer cells through...
B Medical Systems appoint Thierry Goniva as Chief Technology Officer
B Medical Systems, a global pioneer of the medical cold chain industry, has announced the appointment of Thierry Goniva as Chief Technology Officer.
With more...
ACCUVAC-PTE7 cervical cancer vaccine provides complete protection
In a groundbreaking advancement in the treatment of cancer, Defence Therapeutics has revealed that the company’s AccuVAC-PTE7 cervical cancer vaccine completely protects against the...
Aquarate partners with Wirral council to offer hydration monitoring in care homes
Aquarate has announced a new partnership with Wirral Council to offer digital hydration monitoring across care homes.
The partnership will involve the roll-out of Aquarate’s...
B Medical Systems and Etihad Cargo partner to create sustainable transport for pharmaceuticals
B Medical Systems has announced that it has entered into a memorandum of understanding (MOU) with Etihad Cargo to develop sustainable transport solutions for...
Meeting the demand for blood storage and transportation solutions
B Medical Systems, a global leader in cold chain and medical refrigeration products, predicts that there will be a surge in need for blood...
NICE recommends VAZKEPA® (icosapent ethyl) to reduce cardiovascular risk
Icosapent ethyl has been recommended by NICE for use across the NHS in England and Wales to reduce cardiovascular (CV) risk in adult statin-treated...
Defence Therapeutics provides an update on its numerous anti-cancer projects
Biotechnology pioneers Defence Therapeutics outline its current research and development progress in a plethora of anti-cancer endeavours.
In Q1 of 2022, Defence signed an agreement...
B Medical Systems receives WHO prequalification for their U201 Ultra-low freezer
B Medical Systems, a global leader in medical cold chain solutions, has announced that the company’s Ultra-Low Freezer U201 has received the world’s first...
Defence Therapeutics move closer to AccuTOXTM Phase I clinical trial
Defence Therapeutics has established an agreement with CATO SMS, who will advise on submitting the company’s clinical application to Health Canada to initiate a...
Defence Therapeutics’ HPV vaccine achieves a higher humoral response than Gardasil-9
Canadian biotechnology company Defence Therapeutics has revealed that its novel HPV vaccine has demonstrated a higher humoral response than the Gardasil-9 vaccine.
The company’s new...
